Xenetic Biosciences (XBIO) Net Cash Flow (2023 - 2025)
Xenetic Biosciences' Net Cash Flow history spans 7 years, with the latest figure at -$242682.0 for Q4 2025.
- For Q4 2025, Net Cash Flow rose 63.99% year-over-year to -$242682.0; the TTM value through Dec 2025 reached -$2.3 million, up 18.84%, while the annual FY2025 figure was $1.7 million, 160.98% up from the prior year.
- Net Cash Flow reached -$242682.0 in Q4 2025 per XBIO's latest filing, up from -$658247.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of -$242682.0 in Q4 2025 to a low of -$1.3 million in Q2 2023.
- Average Net Cash Flow over 3 years is -$767238.2, with a median of -$733509.5 recorded in 2023.
- The largest YoY upside for Net Cash Flow was 63.99% in 2025 against a maximum downside of 43.4% in 2025.
- A 3-year view of Net Cash Flow shows it stood at -$793027.0 in 2023, then grew by 15.01% to -$673992.0 in 2024, then soared by 63.99% to -$242682.0 in 2025.
- Per Business Quant, the three most recent readings for XBIO's Net Cash Flow are -$242682.0 (Q4 2025), -$658247.0 (Q3 2025), and -$383830.0 (Q2 2025).